Eyeworld

57 EW FEATURE May 2016 • Microinvasive glaucoma surgery (MIGS) Contact information Brown: reaymary@comcast.net Radcliffe: drradcliffe@gmail.com Samuelson: twsamuelson@mneye.com to increase as the options increase. Patients are learning about this, and word of mouth will increase. I think there is going to be a point where cataract surgeons who don't offer MIGS will feel that they really need to and will either begin referring those patients out or learn MIGS to treat glaucoma at the time of cata- ract surgery. I think that the 24% of surgeons currently performing MIGS is going to slowly climb to 100%," he said. Dr. Brown has worked on new glaucoma devices and procedures for 30 years, and he said that it is extremely difficult to get surgeons— especially glaucoma surgeons—to change practice patterns. "Therefore, to me, it is amazing that 50% have already adopted—or are planning to adopt—the iStent. I think the tip- ping point has already been reached. It is just a matter of time before it is the exception when a glaucoma patient does not get an iStent—or some other MIGS technology— when having cataract surgery. The effectiveness of cataract surgery with an iStent in lowering IOP has been well-demonstrated. There also have been major improvements in the ease of implantation, such as a better insertion device and better identification of the canal to ensure accurate placement. After seeing many glaucoma surgical technolo- gies fail over the years due at least in part to the difficulty in overcom- ing surgeon inertia, it is gratifying to see the iStent enthusiastically embraced and become so success- ful," he said. EW Editors' note: Dr. Samuelson has finan- cial interests with Glaukos, Alcon (Fort Worth, Texas), Ivantis (Irvine, Califor- nia), Transcend Medical (Menlo Park, California), and Allergan (Dublin). Dr. Radcliffe has financial interests with Beaver Visitec (Waltham, Massachu- setts), Glaukos, Iridex (Mountain View, California), Transcend Medical, New World Medical (Rancho Cucamonga, California), and Allergan. Dr. Brown has financials interest with Glaukos, Ivantis, and Transcend Medical. Advancing CATARACT SURGERY DisCoVisc ® OPHTHALMIC VISCOSURGICAL DEVICE 1. Vasavada A, Ong M, Cordova D, Hartzer M. Protective effect ophthalmic viscosurgical devices (OVDs) against hydrogen peroxide-induced oxidative damage to corneal endothelial cells: an in-vitro model. Presented at American Society of Cataract and Refractive Surgeons; April 3-8, 2009; San Francisco, CA. 2. Petroll WM, Jafari M, Lane SS, Jester JV, Cavanagh HD. Quantitative assessment of ophthalmic viscosurgical device retention using in vivo confocal microscopy. J Cataract Refract Surg. 2005;31(12):2363-2368. 3. Lindstrom RL, Ong M. Protective effect of OVDs against hydrogen peroxide-induced oxidative damage to corneal endothelial cells: in vitro model. Presented at ASCRS; 26 Mar 2011; San Diego, CA. 4. DisCoVisc ® Package Insert. © 2016 Novartis 2/16 US-VIS-16-E-0527 Trust the adaptive capabilities of DisCoVisc ® OVD to deliver the powerful combination of: • Chondroitin sulfate for superior endothelial protection and retention 1-3 • Mechanical protection, space maintenance and clarity 4 Talk to your Alcon sales representative to learn how all-in-one DisCoVisc ® OVD can exceed your evolving needs. Your technologies and techniques have evolved. It's time to rethink your OVD. UNCOMPROMISING PERFORMANCE IN A SINGLE SYRINGE. 1-4 For important product information, please see adjacent page. Advanced-technology compatible Validated for use with the UltraSert TM Pre-loaded IOL Delivery System Global Trends in Ophthalmology ™ Copyright © 2016 Global Trends in Ophthalmology and the American Society of Cataract & Refractive Surgery. All rights reserved.

• Cover